Modality
Bispecific Ab
MOA
HPK1i
Target
PLK4
Pathway
Cell Cycle
ASMCC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ May 2028
Phase 1Current
NCT03301958
646 pts·MCC
2021-06→2028-05·Terminated
NCT05359294
2,359 pts·MCC
2018-08→2026-10·Completed
3,005 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-066mo awayInterim· MCC
2028-05-012.1y awayInterim· MCC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Complet…
P1
Termina…
Catalysts
Interim
2026-10-06 · 6mo away
MCC
Interim
2028-05-01 · 2.1y away
MCC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03301958 | Phase 1 | MCC | Terminated | 646 | Mayo |
| NCT05359294 | Phase 1 | MCC | Completed | 2359 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |